jnj-78278343
mAbexperimentalBi-specific
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jul 13, 2021 (NCT04898634)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068280 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07225946 | Phase 3 | Jan 15, 2026 | — |
| NCT07164443 | Phase 3 | Sep 2, 2025 | — |
| NCT07082920 | Phase 1 | Jul 7, 2025 | — |
| NCT06095089 | Phase 1 | Nov 1, 2023 | — |
| NCT05818683 | Phase 1 | Apr 26, 2023 | — |
| NCT04898634 | Phase 1 | Jul 13, 2021 | Janssen Pharmaceutica NV |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1